Safety and Efficacy Study of DuoTrav APS Versus DuoTrav
Status:
Withdrawn
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to demonstrate that the IOP-lowering efficacy of DuoTrav APS,
dosed once-daily in the morning, is non-inferior to that of DuoTrav, dosed once-daily in the
morning.